GPR30在乳腺癌患者中的表达及其临床意义  

Expression and clinical significance of GPR30 in breast cancer patients

作　　者：范国宇[1] 刘伟[2] 

机构地区：[1]吉林市中心医院肿瘤四病区,132001 [2]北华大学附属医院肿瘤内科

出　　处：《中国实用医药》2016年第21期12-13,共2页China Practical Medicine

摘　　要：目的研究G蛋白偶联受体30(GPR30)在雌激素受体阴性乳腺癌患者乳腺病理组织中的表达情况及临床意义。方法 123例乳腺癌患者的病理标本,进行免疫组化染色,观察GPR30的表达情况。结果 GPR30表达于63.41%的乳腺癌患者中,ER(+)患者表达率64.29%,其中TAM治疗耐药表达率高达69.23%。结论 GPR30在雌激素受体阴性的乳腺癌内分泌治疗中具有重要作用。Objective To research expression and clinical significance by G protein-coupled receptor 30 （GPR30） in pathological breast tissue of estrogen receptor negative breast cancer patients. Methods A total of 123 pathological samples of breast cancer patients were taken into immumohistochemical staining to observe expression of GPR30. Results GPR30 was shown in 63.41% of breast cancer patients, and patients with ER（＋） had expression rate as 64.29%. TAM treatment showed drug resistance expression rate as 69.23%. Conclusion GPR30 contains important effects in endocrinotherapy for estrogen receptor negative breast cancer.

关 键 词：G蛋白偶联受体30 雌激素受体阴性乳腺癌 内分泌治疗 三阴性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]